Cargando…

CSF sTREM2: marking the tipping point between preclinical AD and dementia?

Biomarkers for Alzheimer's disease (AD) have improved our understanding of the temporal sequence of biological events that lead to AD dementia (Jack et al, 2013). AD is characterized neuropathologically by amyloid plaques comprised of the amyloid‐β peptide and neurofibrillary tangles comprised...

Descripción completa

Detalles Bibliográficos
Autores principales: Schindler, Suzanne E, Holtzman, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125351/
https://www.ncbi.nlm.nih.gov/pubmed/26976613
http://dx.doi.org/10.15252/emmm.201606245
_version_ 1782469966802452480
author Schindler, Suzanne E
Holtzman, David M
author_facet Schindler, Suzanne E
Holtzman, David M
author_sort Schindler, Suzanne E
collection PubMed
description Biomarkers for Alzheimer's disease (AD) have improved our understanding of the temporal sequence of biological events that lead to AD dementia (Jack et al, 2013). AD is characterized neuropathologically by amyloid plaques comprised of the amyloid‐β peptide and neurofibrillary tangles comprised of tau. Brain amyloid deposition, as evidenced by a decline in amyloid‐β peptide 42 (Aβ42) in the cerebrospinal fluid (CSF) or by binding of amyloid PET ligands, is thought to be a key initiating event in AD and begins many years prior to the onset of dementia. A rise in CSF tau and phosphorylated tau in the setting of Aβ deposition appears to reflect neurodegeneration and also begins years prior to the onset of dementia but after Aβ deposition has begun to accumulate. Individuals with “preclinical AD,” that is, normal cognition but abnormal AD biomarkers, have a much higher risk for developing AD dementia but may remain cognitively normal for years (Vos et al, 2013). While deposition of amyloid and formation of tau tangles are necessary for AD to occur, it is likely that additional events involving inflammation or other processes contribute to crossing the tipping point from preclinical AD to AD dementia. Current efforts are aimed at defining the biomarker(s) that best predict the transition from cognitive normality to abnormality. A biomarker that is closely associated with the onset of cognitive decline could help us to understand the biological events that connect amyloid deposition and tangle formation to cognitive decline and could have significant practical value in AD diagnosis and clinical trial design.
format Online
Article
Text
id pubmed-5125351
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-51253512016-12-09 CSF sTREM2: marking the tipping point between preclinical AD and dementia? Schindler, Suzanne E Holtzman, David M EMBO Mol Med News & Views Biomarkers for Alzheimer's disease (AD) have improved our understanding of the temporal sequence of biological events that lead to AD dementia (Jack et al, 2013). AD is characterized neuropathologically by amyloid plaques comprised of the amyloid‐β peptide and neurofibrillary tangles comprised of tau. Brain amyloid deposition, as evidenced by a decline in amyloid‐β peptide 42 (Aβ42) in the cerebrospinal fluid (CSF) or by binding of amyloid PET ligands, is thought to be a key initiating event in AD and begins many years prior to the onset of dementia. A rise in CSF tau and phosphorylated tau in the setting of Aβ deposition appears to reflect neurodegeneration and also begins years prior to the onset of dementia but after Aβ deposition has begun to accumulate. Individuals with “preclinical AD,” that is, normal cognition but abnormal AD biomarkers, have a much higher risk for developing AD dementia but may remain cognitively normal for years (Vos et al, 2013). While deposition of amyloid and formation of tau tangles are necessary for AD to occur, it is likely that additional events involving inflammation or other processes contribute to crossing the tipping point from preclinical AD to AD dementia. Current efforts are aimed at defining the biomarker(s) that best predict the transition from cognitive normality to abnormality. A biomarker that is closely associated with the onset of cognitive decline could help us to understand the biological events that connect amyloid deposition and tangle formation to cognitive decline and could have significant practical value in AD diagnosis and clinical trial design. John Wiley and Sons Inc. 2016-03-14 2016-05 /pmc/articles/PMC5125351/ /pubmed/26976613 http://dx.doi.org/10.15252/emmm.201606245 Text en © 2016 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the Creative Commons Attribution 4.0 (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Views
Schindler, Suzanne E
Holtzman, David M
CSF sTREM2: marking the tipping point between preclinical AD and dementia?
title CSF sTREM2: marking the tipping point between preclinical AD and dementia?
title_full CSF sTREM2: marking the tipping point between preclinical AD and dementia?
title_fullStr CSF sTREM2: marking the tipping point between preclinical AD and dementia?
title_full_unstemmed CSF sTREM2: marking the tipping point between preclinical AD and dementia?
title_short CSF sTREM2: marking the tipping point between preclinical AD and dementia?
title_sort csf strem2: marking the tipping point between preclinical ad and dementia?
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125351/
https://www.ncbi.nlm.nih.gov/pubmed/26976613
http://dx.doi.org/10.15252/emmm.201606245
work_keys_str_mv AT schindlersuzannee csfstrem2markingthetippingpointbetweenpreclinicaladanddementia
AT holtzmandavidm csfstrem2markingthetippingpointbetweenpreclinicaladanddementia